Content deleted Content added
m Task 18 (cosmetic): eval 31 templates: del empty params (4×); hyphenate params (15×); |
Citation bot (talk | contribs) Add: pmc. | You can use this bot yourself. Report bugs here. | Suggested by Abductive | Category:Drug has EMA link | via #UCB_Category 14/614 |
||
Line 211:
===Ovarian cancer===
Sorafenib has been studied as maintenance therapy after ovarian cancer treatment and in combination with chemotherapy for recurrent ovarian cancer but did not show results that led to approval of the drug for these indications.<ref>{{Cite journal|last1=Ciccone|first1=Marcia A.|last2=Maoz|first2=Asaf|last3=Casabar|first3=Jennifer K.|last4=Machida|first4=Hiroko|last5=Mabuchi|first5=Seiji|last6=Matsuo|first6=Koji|date=July 2016|title=Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature|journal=Expert Opinion on Investigational Drugs|volume=25|issue=7|pages=781–796|doi=10.1080/13543784.2016.1181748|issn=1744-7658|pmid=27101098|pmc=7534810|s2cid=28717797}}</ref>
===Brain (recurrent glioblastoma)===
| |||